Biomarkers in kidney fibrosis: are they useful? - Wikidata - awgldk - TriplyDB

Biomarkers in kidney fibrosis: are they useful?

Biomarkers in kidney fibrosis: are they useful?

http://www.wikidata.org/entity/Q26796625

about

Association of Renal Elasticity and Renal Function Progression in Patients with Chronic Kidney Disease Evaluated by Real-Time Ultrasound Elastography.Periostin and Discoidin Domain Receptor 1: New Biomarkers or Targets for Therapy of Renal Disease.Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases Hydrogen Sulfide Mitigates Kidney Injury in High Fat Diet-Induced Obese Mice.Tubulointerstitial Fibrosis of Living Donor Kidneys Associates with Urinary Monocyte Chemoattractant Protein 1.Periostin in kidney diseases.Matrix Metalloproteinase-7 Is a Urinary Biomarker and Pathogenic Mediator of Kidney Fibrosis.The association of angiogenic factors and chronic kidney disease.

P2860

Q30361940-B62FFEF5-D758-4467-B71A-CB188A171BF0 Q33650181-6D77EB8F-8DE2-4A77-AA4F-6293D68121AC Q33838866-06E60880-78D0-4F96-A065-201427D70084 Q37060073-E583FB1D-5CE9-488A-A3AB-13F0D495C71F Q37075292-94A0A288-5220-497A-941F-012ABC730F50 Q47836671-AAB731B0-6EA0-482D-96AF-C0CC6587C7BC Q51511058-21E65503-755C-4441-A324-B3227A521A97 Q55266003-FF7AFD04-4383-4CAF-98B2-45016072A7F0

P2860

Biomarkers in kidney fibrosis: are they useful?

http://www.wikidata.org/entity/Q26796625

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Biomarkers in kidney fibrosis: are they useful?

@ast

Biomarkers in kidney fibrosis: are they useful?

@en

Biomarkers in kidney fibrosis: are they useful?

@nl

type

label

Biomarkers in kidney fibrosis: are they useful?

@ast

Biomarkers in kidney fibrosis: are they useful?

@en

Biomarkers in kidney fibrosis: are they useful?

@nl

prefLabel

Biomarkers in kidney fibrosis: are they useful?

@ast

Biomarkers in kidney fibrosis: are they useful?

@en

Biomarkers in kidney fibrosis: are they useful?

@nl

P1433

Q26796625-900D731D-3B40-4D72-A432-BFD3B961EB4F

P1476

Q26796625-5B9C3E63-4D1F-4CD5-AC85-DC6938131C6D

P2093

Q26796625-B4261FF3-7EEE-4F0F-9B12-A7188432E1A1

Q26796625-FE051526-0802-4444-B595-CA2F33BE535C

P2860

Q26796625-09CDDA9B-FD44-438F-B50E-67856817FC2E

Q26796625-1A0F8DB7-6C5F-477F-AD53-B1DAEB987A1B

Q26796625-51E986BF-D016-49B4-A20F-826BAFF6BC01

Q26796625-58C9E2D7-CEFC-46A5-9DB4-EF8EC5E878B8

Q26796625-5CC8027D-8C42-4BCF-96C5-119778023A21

Q26796625-6A860ED8-3B64-49F1-94C3-3A3F8071CD8A

Q26796625-6BEF7F4A-0007-4CB7-BA8F-4540F52F49C2

Q26796625-6DFB4916-D765-4642-A397-A811E32C7E94

Q26796625-7963BB54-4151-4C52-B3EF-E06946E5E1E4

Q26796625-89C7B9D0-5B21-414A-B122-8E78F44DCD14

P2888

Q26796625-97B3EE0C-4056-46CC-9298-8382FEEA9D3F

P304

Q26796625-C148FFC9-EA25-4D43-B144-1C17D779FD2A

P31

Q26796625-A47AA053-B582-430E-BF5C-A6A56ACE7C80

P3181

Q26796625-4454FDA9-D8B3-44F0-91CF-FEA01E74B2CB

P356

Q26796625-6AF32429-9B3F-4FBC-9143-9AD9DFD51E5E

P433

Q26796625-A70476DA-B2A8-40FF-97E8-E2DB7A079BAD

P478

Q26796625-8C0F5789-BEC7-4AE5-9264-D9012DF62CB7

P577

Q26796625-3EE25524-BFE4-42BA-8401-6514BA81F528

P5875

Q26796625-478C22D3-6BCF-4467-8760-D90D32278ACB

P6179

Q26796625-6989DEEC-2371-4E64-9AC0-5BEF0C193277

P698

Q26796625-35D8E756-5122-48D4-8A73-C03467DBCAB7

P921

Q26796625-634F05CA-BE37-4389-93B9-092C2BFDF22A

P932

Q26796625-B9F26D5B-83CE-456A-9D5F-809216564813

P3181

P356

P1433

Kidney international supplements

P1476

Biomarkers in kidney fibrosis: are they useful?

@en

P2093

Carol A Pollock

http://www.w3.org/2001/XMLSchema#string

Muh Geot Wong

http://www.w3.org/2001/XMLSchema#string

P2860

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond

Mechanistic connection between inflammation and fibrosis

Multiple biomarkers for the prediction of first major cardiovascular events and death.

Problems with risk reclassification methods for evaluating prediction models

Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker.

Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes.

Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes

Cellular and molecular mechanisms of renal fibrosis.

Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers.

P2888

P304

79-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

673355

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/KISUP.2014.15

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278084160

http://www.w3.org/2001/XMLSchema#string

P6179

1030949196

http://www.w3.org/2001/XMLSchema#string

P698

26312155

http://www.w3.org/2001/XMLSchema#string

P921

P932

4536971

http://www.w3.org/2001/XMLSchema#string